Business Context and Reporting Period
Bio-Rad Laboratories, Inc. filed this Form 8-K on June 21, 2005, to report the entry into a material definitive agreement. The filing details the execution of an Amended and Restated Credit Agreement, replacing the previous credit facility dated September 9, 2003, as amended in December 2004.
Key Financial Metrics and Debt Structure
The filing focuses on the company's credit facility rather than operational financial performance metrics such as revenue or profit.
- Maximum Borrowing Capacity: $150,000,000 on a revolving basis.
- Sub-limits: Includes up to $15,000,000 for swingline loans and up to $15,000,000 for letters of credit.
- Expansion Option: Borrowings may be increased by an additional $50,000,000 subject to lender consent and conditions.
- Maturity Date: June 21, 2010.
- Administrative Agent: JPMorgan Chase Bank, N.A.
The filing text does not provide a clear value for current outstanding debt, cash flow, revenue, or profit margins.
Material Changes and Agreement Terms
The primary material change is the restructuring of the company's credit facility. Key terms include:
- Permitted Uses: Funds are designated for permitted acquisitions, working capital, and other general corporate purposes.
- Collateral: Obligations are secured by substantially all tangible and intangible assets (excluding real property).
- Subsidiary Pledges: The company must pledge shares of all active domestic subsidiaries and 65% of shares of first-tier active foreign subsidiaries.
- Guarantees: Material domestic subsidiaries are required to provide guarantees.
Outlook, Risks, and Contingencies
Management commentary regarding future financial performance or specific risks is not included in this filing. The document serves strictly to disclose the terms of the new credit agreement. The primary contingency noted is the requirement for lender consent to increase the borrowing capacity beyond the initial $150 million limit.
Investor Verification Checklist
- Verify the specific interest rate terms and fees associated with the new credit facility, which are not detailed in the summary text.
- Review the attached Exhibits 10.1, 10.2, and 10.3 for detailed covenants and default provisions.
- Confirm the current utilization of the $150 million facility to assess immediate liquidity needs.
- Monitor for any announced acquisitions that would utilize the "permitted acquisitions" clause of the new agreement.